BPC?157 is a synthetic stable pentadecapeptide derived from the partial amino acid sequence of human gastric juice protein Body Protection Compound. It consists of 15 amino acids and is well known for its strong resistance to enzymatic hydrolysis, which allows it to maintain biological activity under diverse in vitro and in vivo preclinical experimental environments.

This peptide is widely adopted in tissue repair related laboratory research. Preclinical studies demonstrate that BPC?157 can modulate multiple biological signaling pathways, promote angiogenesis, stimulate fibroblast proliferation, accelerate the regeneration of damaged epithelial, tendon, ligament, muscle and mucosal tissues. It also exhibits regulatory effects on inflammatory responses, helping to reduce excessive local inflammation during tissue injury recovery processes. Additional research investigates its effects on gastrointestinal mucosal protection, nerve tissue repair and joint damage recovery.

Our BPC?157 is produced using solid-phase peptide synthesis (SPPS). After crude synthesis, preparative HPLC purification is carried out to remove truncated peptide impurities, followed by mass spectrometry (MS) confirmation for molecular identity. Every production batch undergoes full quality control testing including HPLC purity analysis, water content test, residual solvent inspection and microbial limit test. Complete COA with HPLC spectrum and MS data can be supplied upon request. The lyophilized formulation minimizes peptide degradation during shipment and long-term cold preservation. After reconstitution, the peptide solution should be aliquoted and kept at -20°C for long-term storage; repeated freezing and thawing must be avoided to preserve peptide integrity.